The stock of Exact Sciences Corporation (NASDAQ:EXAS) last traded at $96.44, down -1.13% from the previous session.
Data from the available sources indicates that Exact Sciences Corporation (NASDAQ:EXAS) is covered by 22 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $130.00 and a low of $75.00, we find $105.00. Given the previous closing price of $97.54, this indicates a potential upside of 7.65 percent. EXAS stock price is now 5.61% away from the 50-day moving average and 47.56% away from the 200-day moving average. The market capitalization of the company currently stands at $17.07B.
In total, 6 analysts have assigned it a hold rating, and 14 have given it a buy rating. Brokers who have rated the stock have averaged $104.12 as their price target over the next twelve months.
With the price target enhanced from $55 to $85, Craig Hallum Upgraded its rating from Hold to Buy for Exact Sciences Corporation (NASDAQ: EXAS).
In other news, Doyle James Edward, Director sold 2,000 shares of the company’s stock on Jul 27. The stock was sold for $194,840 at an average price of $97.42. Upon completion of the transaction, the Director now directly owns 52,110 shares in the company, valued at $5.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 19, General Counsel Herriott James sold 1,300 shares of the business’s stock. A total of $130,000 was realized by selling the stock at an average price of $100.00. This leaves the insider owning 5,964 shares of the company worth $0.58 million. Insiders disposed of 123,868 shares of company stock worth roughly $11.95 million over the past 1 year. A total of 0.70% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EXAS stock. A new stake in Exact Sciences Corporation shares was purchased by JENNISON ASSOCIATES LLC during the first quarter worth $42,331,000. TWINBEECH CAPITAL LP invested $26,734,000 in shares of EXAS during the first quarter. In the first quarter, ARDEVORA ASSET MANAGEMENT LLP acquired a new stake in Exact Sciences Corporation valued at approximately $18,912,000. HHLR ADVISORS, LTD. acquired a new stake in EXAS for approximately $16,404,000. CONNOR, CLARK & LUNN INVESTMENT MANAGEMENT LTD. purchased a new stake in EXAS valued at around $15,426,000 in the second quarter. In total, there are 846 active investors with 89.30% ownership of the company’s stock.
With an opening price of $96.97 on Tuesday morning, Exact Sciences Corporation (NASDAQ: EXAS) set off the trading day. During the past 12 months, Exact Sciences Corporation has had a low of $29.27 and a high of $100.77. As of last week, the company has a debt-to-equity ratio of 0.78, a current ratio of 3.00, and a quick ratio of 2.60. The fifty day moving average price for EXAS is $91.62 and a two-hundred day moving average price translates $65.68 for the stock.
The latest earnings results from Exact Sciences Corporation (NASDAQ: EXAS) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.42, beating analysts’ expectations of -$0.75 by 0.33. This compares to -$1.04 EPS in the same period last year. The net profit margin was -23.50% and return on equity was -16.60% for EXAS. The company reported revenue of $602.45 million for the quarter, compared to $486.57 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 23.82 percent. For the current quarter, analysts expect EXAS to generate $600.14M in revenue.
Exact Sciences Corporation(EXAS) Company Profile
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test’s performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
